Fellowship · Richmond, VA
Sponsored by Virginia Commonwealth University Health System
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Journal of hepatology · 2023 · 2,696 citations · Arun Sanyal
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology (Baltimore, Md.) · 2023 · 2,397 citations · Arun Sanyal
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
The New England journal of medicine · 2024 · 1,637 citations · Arun Sanyal
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) · 2023 · 2,087 citations · Shadab Siddiqui
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
The New England journal of medicine · 2025 · 750 citations · Arun Sanyal
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
The New England journal of medicine · 2024 · 761 citations · Arun Sanyal
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine · 2021 · 1,609 citations · Arun Sanyal
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Annals of hepatology · 2024 · 542 citations · Arun Sanyal